Abstract |
Kamillosan(R) cream contains chamomile extract as active principle manufactured from the chamomile sort Manzana which is rich in active principles and has been proved not to exhibit a chamomile-related allergen potential. For this reason Kamillosan(R) cream is suited for local therapy of atopic eczema. In a partially double-blind, randomized study carried out as a half-side comparison, Kamillosan(R) cream was tested vs. 0.5% hydrocortisone cream and the vehicle cream as placebo in patients suffering from medium-degree atopic eczema. After a 2-week treatment Kamillosan(R) cream showed a mild superiority towards 0.5% hydrocortisone and a marginal difference as compared to placebo.
|
Authors | R Patzelt-Wenczler, E Ponce-Pöschl |
Journal | European journal of medical research
(Eur J Med Res)
Vol. 5
Issue 4
Pg. 171-5
(Apr 19 2000)
ISSN: 0949-2321 [Print] England |
PMID | 10799352
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Drug Combinations
- Oils, Volatile
- Plant Extracts
- Sesquiterpenes
- Kamillosan
- Arachidonic Acid
- Hydrocortisone
|
Topics |
- Administration, Topical
- Anti-Inflammatory Agents
(administration & dosage)
- Arachidonic Acid
(metabolism)
- Arm
- Chamomile
(therapeutic use)
- Dermatitis, Atopic
(drug therapy)
- Drug Combinations
- Erythema
(drug therapy)
- Humans
- Hydrocortisone
(administration & dosage)
- Middle Aged
- Oils, Volatile
(administration & dosage)
- Phytotherapy
- Plant Extracts
(administration & dosage)
- Plants, Medicinal
- Pruritus
(drug therapy)
- Sesquiterpenes
(administration & dosage)
- Treatment Outcome
|